The effect of transcutaneous auricular vagus nerve stimulation on cardiovascular function in subarachnoid hemorrhage patients: a safety study.

Gansheng TanAnna L HuguenardKara M DonovanPhillip DemarestXiaoxuan LiuZiwei LiMarkus AdamekKory LavineAnanth K VellimanaTerrance T KummerJoshua W OsbunGregory J ZipfelPeter BrunnerEric C Leuthardt

Published in: medRxiv : the preprint server for health sciences (2024)

Our study found that taVNS treatment did not induce adverse cardiovascular effects, such as bradycardia or QT prolongation, supporting its development as a safe immunomodulatory treatment approach for SAH patients. The observed acute increase in heart rate after taVNS treatment may serve as a biomarker for SAH patients who could derive greater benefit from this treatment.

Keyphrases

heart rate
subarachnoid hemorrhage
newly diagnosed
ejection fraction
blood pressure
drug induced
prognostic factors
hepatitis b virus
patient reported outcomes
extracorporeal membrane oxygenation
replacement therapy
smoking cessation
patient reported
adverse drug